Overview Quote
Stock Activity
| Day Low - High | 12.15 - 12.42 |
| 52wk Low - High | 9.37 - 14.55 |
| Previous Close | 12.04 |
| Avg. Volume | 7,107,231 |
| Industry | MED-DRUGS |
| Market Cap | 7.16 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.93 |
| PE (Forward) | 65.08 |
| Current Year Est. | 0.19 |
| Quarterly Earnings ESP |
20.00% |
Premium research
Zacks Rank
|
2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
106 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
Elan Corporation, plc is a leading worldwide specialty pharmaceutical company focused on the discovery, development and marketing of therapeutic products and services in neurology, acute care and pain management and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. The company consists of three operating divisions: Elan Pharmaceuticals, Elan Pharmaceutical Technologies and Elan Pharmaceutical Operations.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.05 | 0.01 | 0.19 | 0.29 |
| Number of Estimates | 2 | 2 | 2 | 2 |
| Low Estimate | 0.04 | -0.01 | 0.12 | 0.17 |
| High Estimate | 0.06 | 0.04 | 0.25 | NA |
| Year Ago EPS | -0.05 | -0.11 | -0.66 | 0.19 |
| EPS Growth | 200.00% | 113.64% | 128.03% | 59.46% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ELAN CP PLC ADR | ELN | 12.04 | ![]() |
![]() |
| JAZZ PHARMACEUT | JAZZ | 61.53 | ![]() |
![]() |
| SALIX PHARM-LTD | SLXP | 59.47 | ![]() |
![]() |
| SANTARUS INC | SNTS | 22.28 | ![]() |
![]() |
| USANA HLTH SCI | USNA | 68.14 | ![]() |
![]() |
| CATALYST PHARMA | CPRX | 0.85 | ![]() |
![]() |
| CELL THERAPEUT | CTIC | 1.29 | ![]() |
![]() |
| CUBIST PHARM | CBST | 56.11 | ![]() |
![]() |
| INFINITY PHARMA | INFI | 23.12 | ![]() |
![]() |
| LANNETT INC | LCI | 12.03 | ![]() |
![]() |
Sector:Medical>> Industry:MED-DRUGS
Zacks Commentary
Alkermes Reports Earnings for Q4
May 23, 2013
Elan Provides Strategic Update
May 21, 2013
Elan in Royalty Deal with THRX
May 14, 2013
Spectrum Pharma Reports 1Q Loss
May 14, 2013
Dendreon Narrows 1Q Loss
May 10, 2013
Santarus Beats on Earnings and Revs
May 08, 2013
Positive Data on Forest Combo Drug
May 07, 2013
Elan Narrows Y/Y Loss
Apr 25, 2013
Financials
| EPS TTM | -0.38 |
| Sales | 1,203 |
| Net Income | -42 |
| Price/Earnings | NA |
| Price/Book | 10.50 |
| Price/Cash Flow | NA |
| Price/Sales | 5.69 |
News
Alkermes Earnings Beat Estimates, But Outlook Unclear - Investors Business Daily
May 23, 2013
Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 - Businesswire
May 23, 2013
Elan Corporation, plc's Board of Directors Unanimously Reject Royalty Pharma's Revised Tender Offer - Businesswire
May 23, 2013
Elan Releases Response to Royalty Pharma Announcement - Close-Up Media
May 23, 2013
Elan Reports Proposed Offering in Aggregate Principal Amount of Senior Notes Due 2021 - Close-Up Media
May 23, 2013
Elan Reports Recent Transactions - Close-Up Media
May 23, 2013
Elan Set to Possibly Pullback After Yesterday's Rally of 2.66% - Comtex Smartrend(R)
May 23, 2013
Market Maker Surveillance Report. ELN, BAC, RAD, T, INTC, MSFT, Bearishly Biased Price Friction For Wednesday, May 22nd 2013 - M2
May 23, 2013
Broker Recommendations
| Current ABR | 2.20 |
| ABR (Last Week) | 2.20 |
| # of recs in ABR | 5 |
| Average Target Price | 12.63 |
| Industry Rank by ABR | 106 out of 265 |
| Rank in Industry | 5 out of 93 |

2